STOCK TITAN

Simulations Plus to Present at Oppenheimer Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that Shawn O’Connor, chief executive officer, will be presenting at Oppenheimer’s 31st Annual Healthcare Conference on Tuesday, March 16, 2021. Mr. O’Connor’s presentation, which will be webcast live, will begin at 2:30 p.m. ET. In addition, Mr. O’Connor and chief financial officer Will Frederick will host one-on-one meetings throughout the day.

The Company’s slide presentation will be available on the Investors page of the Simulations Plus website following the presentation. For more information about the Oppenheimer Annual Healthcare Conference, or to register to attend, please visit the conference website.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our vision is to improve health through innovative solutions, and our mission is to create value for our customers by accelerating and reducing the costs of R&D through innovative science-based software and consulting solutions that optimize treatment options and improve patient lives. For more information, please visit our website at www.simulations-plus.com.

Simulations Plus, Inc.

NASDAQ:SLP

SLP Rankings

SLP Latest News

SLP Stock Data

933.30M
16.19M
18.89%
78.83%
6.01%
Computer Systems Design Services
Professional, Scientific, and Technical Services
Link
United States of America
LANCASTER

About SLP

simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res